2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Abstract Number: 660

Progression of Radiographic Sacroiliitis in Patients with Axial Spondyloarthritis from the Assessment of Spondyloarthritis International Society Cohort on Central Reading – Five-Year Data
Abstract Number: 661

Bridging the Gap between Symptom Onset and Diagnosis in Axial Spondyloarthritis
Abstract Number: 662

Radiographic Progression of Structural Joint Damage in Patients with Active Psoriatic Arthritis Treated with Ixekizumab for up to 3 Years
Abstract Number: 663

Relative Contributions of Improvements in the Psoriasis Area and Severity Index (PASI) and Disease Activity Index for Psoriatic Arthritis (DAPSA) to Improvements in Quality of Life and Function in Patients with Psoriatic Arthritis
Abstract Number: 664

Prevalence and Factors Associated with Peripheral Manifestations in Spondyloarthritis. an Ancillary Analysis of the ASAS-Comospa Study
Abstract Number: 665

Impact of Peripheral Manifestations on Patient-Reported Outcomes (PROs) and Treatment in Spondyloarthritis. Data from ASAS-Comospa
Abstract Number: 666

Inflammation on MRI of the Sacroiliac Joints Is Highly Associated with Structural Damage in Axial Spondyloarthritis Patients in Clinical Practice: Data from the ASAS and DESIR Cohorts
Abstract Number: 667

Assessment of Radiographic Sacroiliitis on Antero-Posterior Lumbar Radiographs As Compared to Conventional Pelvic Radiographs in Patients with Axial Spondyloarthritis
Abstract Number: 668

Progression of Unilateral Grade 2 Sacroiliitis in a Psoriatic Arthritis Cohort
Abstract Number: 669

High Prevalence of Axial Spondyloarthritis in Patients with Acute Anterior Uveitis and Chronic Back Pain – Preliminary Results of a Prospective Observational Study
Abstract Number: 670

Low Rate of Spinal Radiographic Progression over 2 Years in Ankylosing Spondylitis Patients Treated with Secukinumab: A Historical Cohort Comparison
Abstract Number: 671

Validation of the Rexspa (Reductive X-Ray Score for Psoriatic Arthritis) in an Argentinean Cohort of Patients with Psoriatic Arthritis
Abstract Number: 672

Activation of NLRP3 Inflammasomes in Peripheral Blood Mononuclear Cells of Patients with Ankylosing Spondylitis
Abstract Number: 673

Chronic Back Pain (CBP) in First Degree Relatives (FDRs) of Patient with Ankylosing Spondylitis (AS): Comparison with the US Population, HLA-B27 Frequency and Persistence of Symptoms over Time
Abstract Number: 674

Defining the Therapeutic Target in Psoriatic Arthritis: MDA Versus Dapsa

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].